Urinary Tract Infection Testing Market Size to Hit USD 765.9 Million by 2030

The global urinary tract infection testing market size is expected to hit around USD 765.9 million by 2030 from valued at USD 554.1 million in 2021, growing at a CAGR of 3.66% during the forecast period 2022 to 2030.

Report Highlights

• The cystitis segment dominated the market in 2021. 
• Pyelonephritis is anticipated to be the fastest-growing segment in the coming years and is expected to grow at a CAGR of 4.2%.
• The general practitioner segment held a share of 13.33% in 2021. 
• The reference laboratories segment is expected to grow at a CAGR of 3.8%.
• In 2021, North America dominated the overall UTI testing market in terms of value, accounting for a share of nearly 34.25%. 
• The Asia Pacific region is expected to witness the highest CAGR during the forecast period. 
• By type, the U.S. urinary tract infection testing market was valued at USD 171.8 million in 2021 and expected to witness growth at a CAGR of 3.9% from 2022 to 2030.
• The UTI testing market is witnessing growth due to factors such as rising disease burden, increasing geriatric population, rapid technological advancements, and high R&D investments by key players to introduce novel & innovative products, such as self-testing & rapid Point-of-Care (PoC) devices products.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39358

Urinary tract infection is becoming a common global concern. According to research studies, UTI occurs in one in five adult women at some point in their life. In the U.S., about 25%-40% of women aged 20-40 have suffered a UTI. In the U.S., about 250,000 cases of pyelonephritis are reported every year. In women aged 18-19, its incidence is about 28/10,000, out of which 7% of cases require hospital admission. Genetic and cultural factors may influence its prevalence; for instance, in South Korea, the incidence of pyelonephritis is around 59/10,000. Its recurrence is more common than other UTIs, with the recurrence rate being 5.7% in men and 9% in women.

Patients with diabetes are at increased risk of developing urinary tract infections such as acute cystitis, and therefore, the increasing global prevalence of diabetes is likely to contribute to cystitis growth. According to an NCBI article, type 2 diabetes raises UTI risk and patients with type 2 diabetes experience frequent & severe UTIs. According to the International Diabetes Federation (IDF) data from 2021, approximately 643 million individuals will have diabetes by 2030 and 783 million by 2045. Moreover, the estimated prevalence of asymptomatic bacteriuria in diabetic females is 26%, compared to 6% in nondiabetic females. Such factors are expected to boost the prevalence of cystitis globally.

However, due to the rise in awareness about such diseases, the demand for specialist treatment has increased in recent years. According to the U.S. Department of Health and Human Services, in the U.S., the number of practicing urologists in 2020 was 4.07 per 100,000 populations. The report further stated that due to the rise in demand, a shortage of urologists was observed, which is likely to exceed nearly 3,600 physicians by 2025. This can impede market growth in the coming years. Moreover, COVID-19 has had a detrimental impact on the industry. Individuals with UTIs have experienced substantial disruptions in testing and emergency care.

Key players are introducing novel products to strengthen their portfolios. For instance, in September 2021, OpGen, Inc. announced initiating clinical trials of the Unyvero Urinary Tract Infection Panel. The panel can analyze a broad range of pathogens and antimicrobial resistance markers directly from a urine sample. Successful clinical trials and the launch of such technologically advanced & efficient products are anticipated to drive market growth over the coming years. Similarly, in July 2020, Uqora, Inc. (Pharmavite, LLC), a urinary health biotechnology company, launched a UTI diagnostic and management kit. The kit includes a rapid UTI diagnostic device, Clarify, compatible with a PoC and homecare setting.

Scope of The Report

By Type Insights

The cystitis segment dominated the market in 2021. This can be attributed to the high incidence & recurrence rate of cystitis, increased number of product approvals, and the high number of diabetes patients who are more prone to cystitis. According to NCBI’s epidemiology report, globally, acute cystitis occurs in about 10 out of 100 women every year. In addition, its recurrence rate is also high in women; half of the women affected by cystitis have it again within a year.

In addition, pyelonephritis is anticipated to be the fastest-growing segment in the coming years and is expected to grow at a CAGR of 4.2%. due to its growing prevalence. According to NCBI statistics, in the U.S., more than 250,000 cases of pyelonephritis are diagnosed every year. The study further suggested that across the globe, in women aged 18 years to 49 years, there are around 28 pyelonephritis cases per 10,000 individuals.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39358

By End-Use Insights

The general practitioner segment held a share of 13.33% in 2021. This can be attributed to the fact that it is the primary point of contact for most patients with urinary tract infection, and in most cases, uncomplicated UTIs is diagnosed and treated by a general practitioner. According to an American Urological Association article, in the U.S., every year, UTIs contribute to more than 8 to 10 million doctor visits.

The reference laboratories segment is expected to grow at a CAGR of 3.8% due to ongoing efforts to improve patient outcomes by providing diagnostic facilities. In addition, reference labs can handle large volumes of diagnostic tests at an expedited rate and provide better results at comparatively lower prices, which is anticipated to offer economies of scale to service providers.

Regional Insights

In 2021, North America dominated the overall UTI testing market in terms of value, accounting for a share of nearly 34.25%. This can be attributed tothe high disease burden, availability of infrastructure, increased healthcare expenditure, rapid technological advancements, proactive government initiatives, rise in patient awareness, and presence of major players.

In addition, the Asia Pacific region is expected to witness the highest CAGR during the forecast period. The high growth rate can be attributed to the rising disease incidence rate and the high geriatric population. Increasing demand for cost-effective diagnostics and a growing population are among the factors significantly contributing to market growth. Asia Pacific markets such as Australia and South Korea already have a healthcare reimbursement system that provides coverage for UTI diagnostic tests.

Key Players

• QIAGEN
• Accelerate Diagnostics, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• Siemens Healthcare GmbH
• Randox Laboratories Ltd.
• Thermo Fisher Scientific, Inc.
• bioMérieux SA
• T2 Biosystems, Inc.

Market Segmentation

• By Type Scope Outlook
  • Urethritis
  • Cystitis
  • Pyelonephritis
• By End-use Outlook
  • General practitioners (GPs)
  • Urologists
  • Urogynecologists
  • Hospital Laboratories
  • Reference Laboratories
  • Hospital Emergency Departments
  • Urgent Care
  • Others
• By Regional Outlook
  • North America

• • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39358

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333